title: Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
authors.affiliation: Cardiovascular Division, Henry Ford Hospital Henry Ford Health System Center for Clinical Effectiveness, Detroit, Michigan 48202, USA. pmc@mich.com
authors.forename: P A
authors.initials: PA
authors.lastname: McCullough
authors.forename: K R
authors.initials: KR
authors.lastname: Marks
mesh_terms: D000741:Anemia, Aplastic / Q000139:chemically induced; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D003327:Coronary Disease / Q000628:therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006291:Health Policy; D006402:Hematologic Diseases / Q000139:chemically induced / Q000401:mortality; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015999:Multivariate Analysis; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011292:Premedication; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012306:Risk; D015607:Stents; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin